The application of the sister chromatid exchange test for evaluation of the novel anthracycline derivatives. Part I.
In the first part of our study, which involved the evaluation of the potential cytogenetic activity of the novel anthracycline derivatives with respect to adriamycin in the sister chromatid exchange (SCE) test, we explored the possibilities of using the test in our laboratory and attempted to determine the range of investigated concentrations. We found that adriamycin at concentrations of 0.05 microg/mL and 0.1 microg/mL leads to a statistically significant increase in SCE versus control (p<0.01). We also found that adriamycin levels exceeding 0.2 microg/mL were toxic and suppressed lymphocyte proliferation.
Marczewska
Jadwiga
J
Department of Biochemistry and Biopharmaceuticals, National Institute of Public Health, 30/34 Chelmska Str. 00-725 Warsaw, Poland.
Anuszewska
Elzbieta L
EL
Priebe
Waldemar
W
D018943:Anthracyclines / Q000633:toxicity*; D004247:DNA / Q000187:drug effects / Q000235:genetics; D004317:Doxorubicin / Q000633:toxicity; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D009153:Mutagens / Q000633:toxicity*; D012854:Sister Chromatid Exchange / Q000187:drug effects*
D018943:Anthracyclines; D009153:Mutagens; D004317:Doxorubicin; D004247:DNA